NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

AZN’s Ph3 Mystic trial for Inoperable Lung Cancers IMHO should give impetus for $funding for either a combo trial/maybe even a Partnership when one reads their press release below in conjunction with CEO Linda Powers remarks many years ago about the Ph1/2 DIRECT trial at MDAnderson.

IIRC these DIRECT trial patients were truly at “near death” ( forgot the medical terminology: palliative care stage?) for INOPERABLE tumors such as pancreatic and especially lung cancer where I distinctly remember CEO Linda Powers citing a woman having a tumor the size of a golf ball. Well that patient to the bewilderment of one and all,especially her physician said: “She is now living a normal life swimming in her pool daily.”

AZN’s PR on Ph3 today:
http://www.rttnews.com/2955795/astrazeneca-mystic-trial-fails-to-meet-significance-in-overall-survival.aspx

In the primary analysis population of patients, whose tumours express PD-L1 on 25% or more of their cancer cells, Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival compared to SoC chemotherapy.

We remain confident in Imfinzi as the cornerstone of our IO programme and continue to evaluate its potential in ongoing non-small cell lung cancer trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy."

Imfinzi is approved for unresectable, Stage III NSCLC in more than 40 countries, including the US, EU and Japan, based on the Phase III PACIFIC trial..

Years ago I and many others like HopefulSurgOnc, Doc_Logic stated that the properties of DCVax would enhance significantly the response rates on PD-L1 and PD1 for that of the likes of BMY, MRK, AZN etc immuno-oncology efforts.

Here’s some recent Longfellow95 comments that may be appropriate in that context:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141717249

For further parsing of today’as failed Mystic trial please see DewDiligence’s detailed commentary on the board he moderates Biotech Values:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144933189

Special Note: I do not have, as most know,a scientific background.

DIFFERENT STROKES FOR DIFFERENT FOLKS